trial · primary record
Mocertatug rezetecan
Neoplasms, Endometrial
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 610 |
| Primary completion | 2031-09-18 |
| Primary endpoint | Progression free survival (PFS) by BICR assessment |
| Registry ID | NCT07684599 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:35.350Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07684599
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mocertatug rezetecan · compound